{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:47:38Z","timestamp":1793296058637,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970504"],"award-info":[{"award-number":["81970504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-04147-5","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T12:24:07Z","timestamp":1766665447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting the MIR4435-2HG\/miR-29c-3p\/FSP1 axis overcomes lenvatinib resistance by inducing ferroptosis in hepatocellular carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Congyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhandong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"issue":"10360","key":"4147_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet (London England). 2022;400(10360):1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet (London England)"},{"issue":"3","key":"4147_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4147_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/hep.31394","volume":"73","author":"S Caruso","year":"2021","unstructured":"Caruso S, O\u2019Brien DR, Cleary SP, Roberts LR, Zucman-Rossi J. Genetics of hepatocellular carcinoma: approaches to explore molecular diversity. Hepatology (Baltimore, Md). 2021;73(1):14\u201326. https:\/\/doi.org\/10.1002\/hep.31394.","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"4147_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.semcancer.2021.07.017","volume":"86","author":"GP Nagaraju","year":"2022","unstructured":"Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol. 2022;86(3):622\u201332. https:\/\/doi.org\/10.1016\/j.semcancer.2021.07.017.","journal-title":"Semin Cancer Biol"},{"issue":"15","key":"4147_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med"},{"issue":"10126","key":"4147_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London England). 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet (London England)"},{"issue":"3","key":"4147_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664\u201371. https:\/\/doi.org\/10.1002\/ijc.23131.","journal-title":"Int J Cancer"},{"key":"4147_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. https:\/\/doi.org\/10.1155\/2014\/638747.","journal-title":"J Thyroid Res"},{"issue":"2","key":"4147_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","volume":"9","author":"A Jindal","year":"2019","unstructured":"Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221\u201332. https:\/\/doi.org\/10.1016\/j.jceh.2019.01.004.","journal-title":"J Clin Exp Hepatol"},{"issue":"13","key":"4147_CR10","doi-asserted-by":"publisher","first-page":"21516","DOI":"10.18632\/oncotarget.15628","volume":"8","author":"D Ke","year":"2017","unstructured":"Ke D, Li H, Zhang Y, An Y, Fu H, Fang X, et al. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer. Oncotarget. 2017;8(13):21516\u201325. https:\/\/doi.org\/10.18632\/oncotarget.15628.","journal-title":"Oncotarget"},{"key":"4147_CR11","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.tranon.2025.102294","volume":"53","author":"Y Tang","year":"2025","unstructured":"Tang Y, Fan S, Peng R, Liu H, Su B, Tu D, et al. TRIM29 reverses lenvatinib resistance in liver cancer cells by ubiquitinating and degrading YBX1 to inhibit the PI3K\/AKT pathway. Transl Oncol. 2025;53:102294. https:\/\/doi.org\/10.1016\/j.tranon.2025.102294.","journal-title":"Transl Oncol"},{"issue":"8","key":"4147_CR12","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.drudis.2024.104069","volume":"29","author":"FM Fan","year":"2024","unstructured":"Fan FM, Fleishman JS, Chen J, Chen ZS, Dong HH. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma. Drug Discov Today. 2024;29(8):104069. https:\/\/doi.org\/10.1016\/j.drudis.2024.104069.","journal-title":"Drug Discov Today"},{"issue":"10","key":"4147_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/CAD.0000000000001759","volume":"36","author":"H Zhou","year":"2025","unstructured":"Zhou H, Zhang Q, Yang L, Pan Z, Zheng H, Zhang Z, Li D, Li G, Liu X, Bao X, Liu C, Zhang W. Inhibition of nuclear receptor coactivator 5 overcomes acquired lenvatinib resistance driven by protein kinase B-mammalian target of Rapamycin signaling in hepatocellular carcinoma. Anticancer Drugs. 2025;36(10):779\u201387. https:\/\/doi.org\/10.1097\/CAD.0000000000001759.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"4147_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13666","volume":"32","author":"J Wang","year":"2025","unstructured":"Wang J, Shi J, Mi L, Zhao M, Han G, Yin F. Aberrant activation of the PI3K\/AKT\/HIF-1\u03b1 pathway promotes glycolysis and lenvatinib resistance in liver cancer. Mol Med Rep. 2025;32(5):301. https:\/\/doi.org\/10.3892\/mmr.2025.13666.","journal-title":"Mol Med Rep"},{"issue":"4","key":"4147_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02644-1","volume":"42","author":"S Wang","year":"2025","unstructured":"Wang S, Peng R, Chen C, Tu D, Cao J, Su B, et al. FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling. Med Oncol. 2025;42(4):98. https:\/\/doi.org\/10.1007\/s12032-025-02644-1.","journal-title":"Med Oncol"},{"issue":"1","key":"4147_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119617","volume":"1871","author":"J Guo","year":"2024","unstructured":"Guo J, Zhao J. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2024;1871(1):119617. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119617.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"1","key":"4147_CR17","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1186\/s12885-025-15086-9","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Lin Y, Cai H, Zhou T. EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-mediated ferroptosis. BMC Cancer. 2025;25(1):1638. https:\/\/doi.org\/10.1186\/s12885-025-15086-9.","journal-title":"BMC Cancer"},{"issue":"6","key":"4147_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101556","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu M, Liu Y, Zheng J, An X, Wen J, Zhu F, et al. Targeting STARD4\/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma. Genes & diseases. 2025;12(6):101556. https:\/\/doi.org\/10.1016\/j.gendis.2025.101556.","journal-title":"Genes & diseases"},{"issue":"7","key":"4147_CR19","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1007\/s11010-025-05218-x","volume":"480","author":"Z Chen","year":"2025","unstructured":"Chen Z, Ou L, Ma L. SOX11 exacerbates ferroptosis to reduce lenvatinib resistance in liver cancer cells by promoting ubiquitination degradation of SREBF1 through upregulating UBE3A. Mol Cell Biochem. 2025;480(7):4119\u201334. https:\/\/doi.org\/10.1007\/s11010-025-05218-x.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"4147_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114389","volume":"444","author":"Y Liu","year":"2025","unstructured":"Liu Y, Chen M, Wang XX, Gao Y, Han X, Wang S, et al. Targeting METTL8 with Rabdosiin overcomes lenvatinib resistance in hepatocellular carcinoma. Exp Cell Res. 2025;444(2):114389. https:\/\/doi.org\/10.1016\/j.yexcr.2024.114389.","journal-title":"Exp Cell Res"},{"issue":"7\u20138","key":"4147_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s10495-024-01967-0","volume":"29","author":"X Liu","year":"2024","unstructured":"Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L, Liu S, Cong W, Lu S, Hou L, Wang B, Li N. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K\/AKT\/p53 signaling axis. Apoptosis: Int J Program Cell Death. 2024;29(7\u20138):1161\u201384. https:\/\/doi.org\/10.1007\/s10495-024-01967-0.","journal-title":"Apoptosis: Int J Program Cell Death"},{"issue":"5","key":"4147_CR22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell"},{"issue":"4","key":"4147_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382. https:\/\/doi.org\/10.1038\/s41580-020-00324-8.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"4147_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273\u201385. https:\/\/doi.org\/10.1016\/j.cell.2017.09.021.","journal-title":"Cell"},{"key":"4147_CR25","doi-asserted-by":"publisher","unstructured":"Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow,B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., Viswanathan, S.R., Chattopadhyay, S., Tamayo, P., Yang, W. S., Rees, M. G., Chen, S., Boskovic, Z.V., Javaid, S., Huang, C., Wu, X., \u2026 Schreiber, S. L. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 547(7664), 453\u2013457. https:\/\/doi.org\/10.1038\/nature2300.","DOI":"10.1038\/nature2300."},{"issue":"7679","key":"4147_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247\u201350. https:\/\/doi.org\/10.1038\/nature24297.","journal-title":"Nature"},{"issue":"7823","key":"4147_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","volume":"585","author":"JM Ubellacker","year":"2020","unstructured":"Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, Gu Z, McCormick ML, Durham AB, Spitz DR, Zhao Z, Mathews TP, Morrison SJ. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585(7823):113\u20138. https:\/\/doi.org\/10.1038\/s41586-020-2623-z.","journal-title":"Nature"},{"issue":"4","key":"4147_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2021.12.001","volume":"82","author":"R Rodriguez","year":"2022","unstructured":"Rodriguez R, Schreiber SL, Conrad M. Persister cancer cells: iron addiction and vulnerability to ferroptosis. Mol Cell. 2022;82(4):728\u201340. https:\/\/doi.org\/10.1016\/j.molcel.2021.12.001.","journal-title":"Mol Cell"},{"issue":"5","key":"4147_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1165\/rcmb.2023-0467OC","volume":"72","author":"Y Yang","year":"2025","unstructured":"Yang Y, Shen W, Zhang Z, Dai Y, Zhang Z, Liu T, Yu J, Huang S, Ding Y, You R, Wang Z, Wu Y, Bian T. FSP1 acts in parallel with GPX4 to inhibit ferroptosis in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2025;72(5):551\u201362. https:\/\/doi.org\/10.1165\/rcmb.2023-0467OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7784","key":"4147_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1707-0.","journal-title":"Nature"},{"issue":"7784","key":"4147_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, Olzmann JA. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688\u201392. https:\/\/doi.org\/10.1038\/s41586-019-1705-2.","journal-title":"Nature"},{"issue":"9","key":"4147_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molmed.2023.05.013","volume":"29","author":"W Li","year":"2023","unstructured":"Li W, Liang L, Liu S, Yi H, Zhou Y. FSP1: a key regulator of ferroptosis. Trends Mol Med. 2023;29(9):753\u201364. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.013.","journal-title":"Trends Mol Med"},{"issue":"6","key":"4147_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12061218","volume":"12","author":"J Lee","year":"2023","unstructured":"Lee J, Roh JL. Unleashing ferroptosis in human cancers: targeting ferroptosis suppressor protein 1 for overcoming therapy resistance. Antioxidants (Basel, Switzerland). 2023;12(6):1218. https:\/\/doi.org\/10.3390\/antiox12061218.","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"10","key":"4147_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70495","volume":"15","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yang S, Huang L, Liu X, Han Q, Niu Q, et al. MUC1 drives ferroptosis resistance in ICC via Src-mediated FSP1 deubiquitination and myristoylation. Clin Transl Med. 2025;15(10):e70495. https:\/\/doi.org\/10.1002\/ctm2.70495.","journal-title":"Clin Transl Med"},{"issue":"1","key":"4147_CR35","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1038\/s41467-023-41626-7","volume":"14","author":"Y Lv","year":"2023","unstructured":"Lv Y, Liang C, Sun Q, Zhu J, Xu H, Li X, et al. Structural insights into FSP1 catalysis and ferroptosis inhibition. Nat Commun. 2023;14(1):5933. https:\/\/doi.org\/10.1038\/s41467-023-41626-7.","journal-title":"Nat Commun"},{"issue":"7969","key":"4147_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41586-023-06255-6","volume":"619","author":"T Nakamura","year":"2023","unstructured":"Nakamura T, Hipp C, Santos Dias Mour\u00e3o A, Borggr\u00e4fe J, Aldrovandi M, Henkelmann B, Wanninger J, Mishima E, Lytton E, Emler D, Proneth B, Sattler M, Conrad M. Phase separation of FSP1 promotes ferroptosis. Nature. 2023;619(7969):371\u20137. https:\/\/doi.org\/10.1038\/s41586-023-06255-6.","journal-title":"Nature"},{"issue":"3","key":"4147_CR37","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1002\/mco2.479","volume":"5","author":"S Feng","year":"2024","unstructured":"Feng S, Huang X, Tang D, Liu X, Ouyang L, Yang D, Wang K, Liao B, Qi S. The crystal structure of human ferroptosis suppressive protein 1 in complex with flavin adenine dinucleotide and nicotinamide adenine nucleotide. MedComm. 2024;5(3):e479. https:\/\/doi.org\/10.1002\/mco2.479.","journal-title":"MedComm"},{"issue":"1","key":"4147_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2025.101633","volume":"20","author":"K Warasnhe","year":"2025","unstructured":"Warasnhe K, Sano A, Guo Q, Satthawiwat N, Dai X, Classon PA, et al. Glycogen synthase kinase 3 \u03b2 hepatocyte deletion attenuates ferroptosis and metabolic dysfunction-associated steatohepatitis in mice. Cell Mol Gastroenterol Hepatol. 2025;20(1):101633. https:\/\/doi.org\/10.1016\/j.jcmgh.2025.101633.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"4147_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13578-015-0050-x","volume":"5","author":"Y Yang","year":"2015","unstructured":"Yang Y, Wen L, Zhu H. Unveiling the hidden function of long non-coding RNA by identifying its major partner-protein. Cell Biosci. 2015;5:59. https:\/\/doi.org\/10.1186\/s13578-015-0050-x.","journal-title":"Cell Biosci"},{"issue":"6","key":"4147_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4161\/rna.20481","volume":"9","author":"T Gutschner","year":"2012","unstructured":"Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703\u201319. https:\/\/doi.org\/10.4161\/rna.20481.","journal-title":"RNA Biol"},{"issue":"12","key":"4147_CR41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.710","volume":"42","author":"S Loewer","year":"2010","unstructured":"Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, Garber M, Curran M, Onder T, Agarwal S, Manos PD, Datta S, Lander ES, Schlaeger TM, Daley GQ, Rinn JL. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113\u20137. https:\/\/doi.org\/10.1038\/ng.710.","journal-title":"Nat Genet"},{"issue":"1","key":"4147_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.devcel.2013.03.002","volume":"25","author":"Y Wang","year":"2013","unstructured":"Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous MiRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell. Dev Cell. 2013;25(1):69\u201380. https:\/\/doi.org\/10.1016\/j.devcel.2013.03.002.","journal-title":"Dev Cell"},{"issue":"4","key":"4147_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10266-020-00488-x","volume":"108","author":"H Shen","year":"2020","unstructured":"Shen H, Sun B, Yang Y, Cai X, Bi L, Deng L, Zhang L. MIR4435-2HG regulates cancer cell behaviors in oral squamous cell carcinoma cell growth by upregulating TGF-\u03b21. Odontology. 2020;108(4):553\u20139. https:\/\/doi.org\/10.1007\/s10266-020-00488-x.","journal-title":"Odontology"},{"issue":"18","key":"4147_CR44","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1111\/febs.15233","volume":"287","author":"S Zhang","year":"2020","unstructured":"Zhang S, Li C, Liu J, Geng F, Shi X, Li Q, et al. Fusobacterium nucleatum promotes epithelial-mesenchymal transition through regulation of the lncRNA MIR4435-2HG\/miR-296-5p\/Akt2\/SNAI1 signaling pathway. FEBS J. 2020;287(18):4032\u201347. https:\/\/doi.org\/10.1111\/febs.15233.","journal-title":"FEBS J"},{"issue":"2","key":"4147_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.taap.2015.04.003","volume":"285","author":"Q Yang","year":"2015","unstructured":"Yang Q, Xu E, Dai J, Liu B, Han Z, Wu J, et al. A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by Resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015;285(2):79\u201388. https:\/\/doi.org\/10.1016\/j.taap.2015.04.003.","journal-title":"Toxicol Appl Pharmacol"},{"key":"4147_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112971","volume":"150","author":"M Zhang","year":"2022","unstructured":"Zhang M, Yu X, Zhang Q, Sun Z, He Y, Guo W. MIR4435-2HG: a newly proposed lncRNA in human cancer. Biomed Pharmacother. 2022;150:112971. https:\/\/doi.org\/10.1016\/j.biopha.2022.112971.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4147_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-023-00493-2","volume":"28","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Xiao B, Liu M, Chen M, Xia N, Guo H, et al. N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2\u2019-O methylation. Cell Mol Biol Lett. 2023;28(1):89. https:\/\/doi.org\/10.1186\/s11658-023-00493-2.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"4147_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06128-8","volume":"23","author":"B Xie","year":"2025","unstructured":"Xie B, Wu P, Liu H, Yang X, Huang L. Long non-coding RNA MIR4435-2HG modulates pancreatic cancer stem cells and chemosensitivity to gemcitabine by targeting the miR-1252-5p\/STAT1. J Transl Med. 2025;23(1):165. https:\/\/doi.org\/10.1186\/s12967-025-06128-8.","journal-title":"J Transl Med"},{"issue":"10","key":"4147_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202400663","volume":"25","author":"X Zhuang","year":"2025","unstructured":"Zhuang X, Jin J, Cheng J, Chen Z, Zhu W, Huang X, et al. P65-driven MIR4435-2HG enhances prognostic value and mediates oxaliplatin resistance via the miR-378G\/ABCB9 axis in colorectal cancer. Macromol Biosci. 2025;25(10):e00663. https:\/\/doi.org\/10.1002\/mabi.202400663.","journal-title":"Macromol Biosci"},{"issue":"5","key":"4147_CR50","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s13402-023-00826-5","volume":"46","author":"L Pei","year":"2023","unstructured":"Pei L, Yan D, He Q, Kong J, Yang M, Ruan H, Lin Q, Huang L, Huang J, Lin T, Qin H. LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder. Cell Oncol (Dordrecht Netherlands). 2023;46(5):1509\u201327. https:\/\/doi.org\/10.1007\/s13402-023-00826-5.","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"issue":"9","key":"4147_CR51","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/2326-6066.CIR-21-1011","volume":"10","author":"H Yu","year":"2022","unstructured":"Yu H, Chen C, Han F, Tang J, Deng M, Niu Y, Lai M, Zhang H. Long noncoding RNA MIR4435-2HG suppresses colorectal cancer initiation and progression by reprogramming neutrophils. Cancer Immunol Res. 2022;10(9):1095\u2013110. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-1011.","journal-title":"Cancer Immunol Res"},{"key":"4147_CR52","doi-asserted-by":"publisher","first-page":"1439485","DOI":"10.3389\/fimmu.2024.1439485","volume":"15","author":"JX Liu","year":"2024","unstructured":"Liu JX, Zhang X, Xu WH, Hao XD. The role of RNA modifications in hepatocellular carcinoma: functional mechanism and potential applications. Front Immunol. 2024;15:1439485. https:\/\/doi.org\/10.3389\/fimmu.2024.1439485.","journal-title":"Front Immunol"},{"issue":"1","key":"4147_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"M Huang","year":"2023","unstructured":"Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2023;83(1):89\u2013102. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0963.","journal-title":"Cancer Res"},{"key":"4147_CR54","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2147\/JHC.S411806","volume":"10","author":"M Tao","year":"2023","unstructured":"Tao M, Han J, Shi J, Liao H, Wen K, Wang W, et al. Application and resistance mechanisms of lenvatinib in patients with advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1069\u201383. https:\/\/doi.org\/10.2147\/JHC.S411806.","journal-title":"J Hepatocell Carcinoma"},{"issue":"8","key":"4147_CR55","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M, et al. Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy. Liver Int. 2024;44(8):1808\u201331. https:\/\/doi.org\/10.1111\/liv.15953.","journal-title":"Liver Int"},{"issue":"4","key":"4147_CR56","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.3892\/mmr.2017.7081","volume":"16","author":"B Liu","year":"2017","unstructured":"Liu B, Pan CF, Ma T, Wang J, Yao GL, Wei K, Chen YJ. Long non-coding RNA AK001796 contributes to cisplatin resistance of non-small cell lung cancer. Mol Med Rep. 2017;16(4):4107\u201312. https:\/\/doi.org\/10.3892\/mmr.2017.7081.","journal-title":"Mol Med Rep"},{"issue":"11","key":"4147_CR57","doi-asserted-by":"publisher","first-page":"e0223035","DOI":"10.1371\/journal.pone.0223035","volume":"15","author":"P Luo","year":"2020","unstructured":"Luo P, Wu S, Ji K, Yuan X, Li H, Chen J, et al. LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1. PLoS One. 2020;15(11):e0223035. https:\/\/doi.org\/10.1371\/journal.pone.0223035.","journal-title":"PLoS One"},{"issue":"9","key":"4147_CR58","doi-asserted-by":"publisher","first-page":"14860","DOI":"10.1002\/jcb.28747","volume":"120","author":"AN Liu","year":"2019","unstructured":"Liu AN, Qu HJ, Gong WJ, Xiang JY, Yang MM, Zhang W. LncRNA AWPPH and miRNA-21 regulates cancer cell proliferation and chemosensitivity in triple-negative breast cancer by interacting with each other. J Cell Biochem. 2019;120(9):14860\u20136. https:\/\/doi.org\/10.1002\/jcb.28747.","journal-title":"J Cell Biochem"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-04147-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04147-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04147-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:56:01Z","timestamp":1769518561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-04147-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4147"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-04147-5","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the AVMA Guidelines for the Euthanasia of Animals. Approval was granted by the Ethics Committee of The Third Hospital of Hebei Medical University (Approval No. W2024-004-1). All procedures involving animals were conducted in compliance with institutional and national guidelines for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.\u00a0","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration"}}],"article-number":"46"}}